or Try an Advanced Search...

    Lupus Nephritis Stocks List

    Symbol Grade Name % Change
    KYTX F Kyverna Therapeutics, Inc. -7.98
    AUPH F Aurinia Pharmaceuticals Inc -0.67
    BIIB C Biogen Idec Inc. -1.21
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Lupus Autoimmune Disease Biopharmaceutical Immunosuppressants Medicine Multiple Sclerosis Nephritis Alzheimer's Disease Autoimmune Disorders Autoimmunity Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia

    Related ETFs - A few ETFs which own one or more of the above listed Lupus Nephritis stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.12
    IBRN C iShares Neuroscience and Healthcare ETF 4.82
    PBE C PowerShares Dynamic Biotech & Genome 4.61
    DIP A BTD Capital Fund 4.41
    BBH D Market Vectors Biotech ETF 4.17
    View all Lupus Nephritis ETFs...
    Compare ETFs
    Compare BIS to DIP Compare DIP to BBH Compare PBE to BBH

        Lupus Nephritis Stocks Recent News

        Date Stock Title
        May 2 BIIB Biogen Reports Progress on Corporate Responsibility Priorities
        May 2 AUPH Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
        May 2 AUPH Aurinia Pharma GAAP EPS of -$0.07 beats by $0.07, revenue of $50.3M beats by $3.23M
        May 2 AUPH Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
        May 1 AUPH Aurinia Pharma Q1 2024 Earnings Preview
        May 1 BIIB Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
        May 1 AUPH Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
        Apr 30 BIIB Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
        Apr 30 AUPH Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going
        Apr 30 BIIB Biogen: Don't Overthink This One
        Apr 30 AUPH Aurinia gains on Lupkynis label update
        Apr 30 AUPH The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
        Apr 29 KYTX Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
        Apr 29 BIIB The Analyst Landscape: 27 Takes On Biogen
        Apr 29 BIIB 10 Most Promising Stocks to Buy Before They Take Off
        Apr 29 BIIB Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
        Apr 29 BIIB Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
        Apr 28 BIIB Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Apr 27 BIIB Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
        Apr 26 BIIB Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Lupus Autoimmune Disease Biopharmaceutical Immunosuppressants Medicine Multiple Sclerosis Nephritis Alzheimer's Disease Autoimmune Disorders Autoimmunity Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia
        Lupus Nephritis

        Lupus nephritis (also known as SLE nephritis) is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. It is a type of glomerulonephritis in which the glomeruli become inflamed. As the result of SLE, the cause of glomerulonephritis is said to be secondary and has a different pattern and outcome from conditions with a primary cause originating in the kidney.

        More about Lupus Nephritis
        Browse All Tags